View Item 

Show simple item record

Prediction of Postchemotherapy Ovarian Function Using Markers of Ovarian Reserve
dc.contributor.authorHenry, N. Lynn
dc.contributor.authorXia, Rong
dc.contributor.authorSchott, Anne F.
dc.contributor.authorMcConnell, Daniel
dc.contributor.authorBanerjee, Mousumi
dc.contributor.authorHayes, Daniel F.
dc.date.accessioned2017-12-15T16:49:07Z
dc.date.available2017-12-15T16:49:07Z
dc.date.issued2014-01
dc.identifier.citationHenry, N. Lynn; Xia, Rong; Schott, Anne F.; McConnell, Daniel; Banerjee, Mousumi; Hayes, Daniel F. (2014). "Prediction of Postchemotherapy Ovarian Function Using Markers of Ovarian Reserve." The Oncologist 19(1): 68-74.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/140040
dc.publisherAlphaMed Press
dc.publisherWiley Periodicals, Inc.
dc.subject.otherOvarian function
dc.subject.otherChemotherapy
dc.subject.otherBreast cancer
dc.subject.otherAnti‐Müllerian hormone
dc.titlePrediction of Postchemotherapy Ovarian Function Using Markers of Ovarian Reserve
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan, USA
dc.contributor.affiliationumBreast Oncology Program, University of Michigan Comprehensive Cancer Center
dc.contributor.affiliationotherDepartment of Biostatistics, and
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/140040/1/onco0068.pdf
dc.identifier.doi10.1634/theoncologist.2013-0145
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceHJ Burstein, E Mayer, AH Patridge. Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: Cases and lessons. Clin Breast Cancer. 2006; 7: 158 – 161.
dc.identifier.citedreferencePJ Goodwin, M Ennis, KI Pritchard. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol. 1999; 17: 2365 – 2370.
dc.identifier.citedreferencePA Ganz, JH Rowland, K Desmond. Life after breast cancer: Understanding women’s health‐related quality of life and sexual functioning. J Clin Oncol. 1998; 16: 501 – 514.
dc.identifier.citedreferenceLT Shuster, DJ Rhodes, BS Gostout. Premature menopause or early menopause: Long‐term health consequences. Maturitas. 2010; 65: 161 – 166.
dc.identifier.citedreferenceJA Petrek, MJ Naughton, LD Case. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol. 2006; 24: 1045 – 1051.
dc.identifier.citedreferenceP Sukumvanich, LD Case, K Van Zee. Incidence and time course of bleeding after long‐term amenorrhea after breast cancer treatment: A prospective study. Cancer. 2010; 116: 3102 – 3111.
dc.identifier.citedreferenceR Fanchin, LM Schonäuer, C Righini. Serum anti‐Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003; 18: 323 – 327.
dc.identifier.citedreferencevan IA Rooij, FJ Broekmans, te ER Velde. Serum anti‐Müllerian hormone levels: A novel measure of ovarian reserve. Hum Reprod. 2002; 17: 3065 – 3071.
dc.identifier.citedreferencevan IA Rooij, FJ Broekmans, GJ Scheffer. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: A longitudinal study. Fertil Steril. 2005; 83: 979 – 987.
dc.identifier.citedreferenceA Pellicer, G Ardiles, F Neuspiller. Evaluation of the ovarian reserve in young low responders with normal basal levels of follicle‐stimulating hormone using three‐dimensional ultrasonography. Fertil Steril. 1998; 70: 671 – 675.
dc.identifier.citedreferenceC Anders, PK Marcom, B Peterson. A pilot study of predictive markers of chemotherapy‐related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008; 26: 286 – 295.
dc.identifier.citedreferenceRA Anderson, DA Cameron. Pretreatment serum anti‐müllerian hormone predicts long‐term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011; 96: 1336 – 1343.
dc.identifier.citedreferenceSJ Lee, LR Schover, AH Partridge. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006; 24: 2917 – 2931.
dc.identifier.citedreferenceHJ Burstein, AA Prestrud, J Seidenfeld. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor‐positive breast cancer. J Clin Oncol. 2010; 28: 3784 – 3796.
dc.identifier.citedreferenceIE Smith, M Dowsett, Y‐S Yap. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy‐induced amenorrhoea: Caution and suggested guidelines. J Clin Oncol. 2006; 24: 2444 – 2447.
dc.identifier.citedreferenceJF Randolph Jr, M Sowers, EB Gold. Reproductive hormones in the early menopausal transition: Relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab. 2003; 88: 1516 – 1522.
dc.identifier.citedreferenceN Santoro, SL Crawford, JE Allsworth. Assessing menstrual cycles with urinary hormone assays. Am J Physiol Endocrinol Metab. 2003; 284: E521 – E530.
dc.identifier.citedreferenceRJ Santen, L Demers, S Ohorodnik. Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids. 2007; 72: 666 – 671.
dc.identifier.citedreferenceAH Partridge, KJ Ruddy, S Gelber. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010; 94: 638 – 644.
dc.identifier.citedreferenceHI Su, MD Sammel, J Green. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors. Cancer. 2010; 116: 592 – 599.
dc.identifier.citedreferenceB Yu, N Douglas, MJ Ferin. Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy. Cancer. 2010; 116: 2099 – 2105.
dc.identifier.citedreferenceNL Henry, R Xia, M Banerjee. Predictors of recovery of ovarian function during aromatase inhibitor therapy. Ann Oncol. 2013; 24: 2011 – 2016.
dc.identifier.citedreferenceHI Su, K Chung, MD Sammel. Antral follicle count provides additive information to hormone measures for determining ovarian function in breast cancer survivors. Fertil Steril. 2011; 95: 1857 – 1859.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0068.pdf
Size:
1.277MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.